These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18719056)

  • 1. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension.
    Chin KM; Channick RN; de Lemos JA; Kim NH; Torres F; Rubin LJ
    Chest; 2009 Jan; 135(1):130-136. PubMed ID: 18719056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels.
    Chin KM; Channick RN; Kim NH; Rubin LJ
    Chest; 2007 Sep; 132(3):786-92. PubMed ID: 17646224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid initiation of intravenous epoprostenol infusion is the favored option in patients with advanced pulmonary arterial hypertension.
    Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Kuwana M; Fukuda K; Satoh T
    PLoS One; 2015; 10(4):e0121894. PubMed ID: 25844932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol.
    Sitbon O; McLaughlin VV; Badesch DB; Barst RJ; Black C; Galiè N; Humbert M; Rainisio M; Rubin LJ; Simonneau G
    Thorax; 2005 Dec; 60(12):1025-30. PubMed ID: 16055621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study.
    Chin KM; Badesch DB; Robbins IM; Tapson VF; Palevsky HI; Kim NH; Kawut SM; Frost A; Benton WW; Lemarie JC; Bodin F; Rubin LJ; McLaughlin V
    Am Heart J; 2014 Feb; 167(2):218-225.e1. PubMed ID: 24439983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
    Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM
    J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epoprostenol sodium for treatment of pulmonary arterial hypertension.
    Saito Y; Nakamura K; Akagi S; Sarashina T; Ejiri K; Miura A; Ogawa A; Matsubara H; Ito H
    Vasc Health Risk Manag; 2015; 11():265-70. PubMed ID: 25999730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute hemodynamic effects of intravenous adenosine in patients with associated pulmonary arterial hypertension: Comparison with intravenous epoprostenol.
    Rossi R; Coppi F; Sgura F; Monopoli D; Boriani G
    Pulm Pharmacol Ther; 2018 Apr; 49():147-151. PubMed ID: 28642014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
    Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L; Barst RJ; Rowan CA; Kerstein D; Rosenzweig EB
    Am J Cardiol; 2010 May; 105(10):1485-9. PubMed ID: 20451700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial.
    Badesch DB; Tapson VF; McGoon MD; Brundage BH; Rubin LJ; Wigley FM; Rich S; Barst RJ; Barrett PS; Kral KM; Jöbsis MM; Loyd JE; Murali S; Frost A; Girgis R; Bourge RC; Ralph DD; Elliott CG; Hill NS; Langleben D; Schilz RJ; McLaughlin VV; Robbins IM; Groves BM; Shapiro S; Medsger TA
    Ann Intern Med; 2000 Mar; 132(6):425-34. PubMed ID: 10733441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry.
    Bergot E; Sitbon O; Cottin V; Prévot G; Canuet M; Bourdin A; de Groote P; Rottat L; Gressin V; Jaïs X; Humbert M; Simonneau G
    Int J Cardiol; 2014 Apr; 172(3):561-7. PubMed ID: 24529947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension.
    Walkey AJ; Fein D; Horbowicz KJ; Farber HW
    Pulm Pharmacol Ther; 2011 Aug; 24(4):421-5. PubMed ID: 21251994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease.
    Thomas IC; Glassner-Kolmin C; Gomberg-Maitland M
    Int J Cardiol; 2013 Oct; 168(4):4117-21. PubMed ID: 23890862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension.
    Sitbon O; Delcroix M; Bergot E; Boonstra AB; Granton J; Langleben D; Subías PE; Galiè N; Pfister T; Lemarié JC; Simonneau G
    Am Heart J; 2014 Feb; 167(2):210-7. PubMed ID: 24439982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival of patients with pulmonary arterial hypertension recovering to World Health Organization functional class I or II: a historical comparison between intravenous epoprostenol and oral agents.
    Yamamoto K; Takeda Y; Takeda Y; Naniwa T; Narita H; Ohte N
    BMC Res Notes; 2014 Jun; 7():359. PubMed ID: 24920465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?
    Barst R
    Int J Clin Pract Suppl; 2010 Nov; (168):23-32. PubMed ID: 20939843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.
    Humbert M; Sanchez O; Fartoukh M; Jagot JL; Le Gall C; Sitbon O; Parent F; Simonneau G
    Eur Respir J; 1999 Jun; 13(6):1351-6. PubMed ID: 10445611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.